N-{1-[({(3R)-1-[3,5-bis(trifluoromethyl)benzyl]-2,5-dioxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl}amino)carbonyl]cyclopropyl}-4-fluorobenzamide | 1227260-99-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-{1-[({(3R)-1-[3,5-bis(trifluoromethyl)benzyl]-2,5-dioxo-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl}amino)carbonyl]cyclopropyl}-4-fluorobenzamide
• 英文别名: (3R)-1-[3,5-Bis(trifluoromethyl)benzyl]-3-[1-(4-fluorobenzoylamino)cyclopropylcarbonylamino]-2,3,4,5-tetrahydro-1H-1-benzoazepine-2,5-dione；N-[1-[[(3R)-1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2,5-dioxo-3,4-dihydro-1-benzazepin-3-yl]carbamoyl]cyclopropyl]-4-fluorobenzamide
• CAS: 1227260-99-2
• 化学式: C₃₀H₂₂F₇N₃O₄
• 分子量: 621.511
• InChiKey: RPLJQDZJOINKCD-JOCHJYFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  44
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  95.6
• 氢给体数：
  2
• 氢受体数：
  11

文献信息

• AZEPINONE DERIVATIVES
  申请人：Okamoto Osamu

  公开号：US20110212891A1

  公开（公告）日：2011-09-01

  The present invention relates to a compound represented by formula (I): wherein R 1 represents a hydrogen atom or the like; R 2 and R 3 represent a hydrogen atom or the like; R 4 is a group represented by (II) R 5 represents a phenyl group which may be substituted with a halogen or the like; m is an integer of from 1 to 3; and p is an integer of from 0 to 4; or a pharmaceutically acceptable salt thereof.

  本发明涉及一种由以下式（I）表示的化合物：其中R1代表氢原子或类似物；R2和R3代表氢原子或类似物；R4是由（II）表示的基团；R5代表可能被卤素或类似物取代的苯基；m为1至3的整数；p为0至4的整数；或其药学上可接受的盐。
• Method for Stimulating Axonal Regeneration
  申请人：The Hong Kong University of Science and Technology

  公开号：US20220160897A1

  公开（公告）日：2022-05-26

  A method of promoting axonal regeneration can include directing neuronal lipid synthesis away from triglyceride synthesis and toward phospholipid synthesis. The method can include administering to the patient a therapeutically effective amount of an inhibitor compound selected from the group consisting of a Lipin-1 inhibitor, a diglyceride acyltransferase inhibitor, and combinations thereof or administering a gene editing therapy to the patient that reduces expression of LIPIN1 or a diglyceride acyltransferase gene.